Boston Scientific Corporation Company Profile (NYSE:BSX)

About Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:BSX
  • CUSIP: 10113710
  • Web:
  • Market Cap: $37.04 billion
  • Outstanding Shares: 1,369,401,000
Average Prices:
  • 50 Day Moving Avg: $27.74
  • 200 Day Moving Avg: $25.82
  • 52 Week Range: $19.67 - $28.51
  • Trailing P/E Ratio: 86.70
  • Foreward P/E Ratio: 19.46
  • P/E Growth: 2.23
Sales & Book Value:
  • Annual Revenue: $8.58 billion
  • Price / Sales: 4.32
  • Book Value: $5.15 per share
  • Price / Book: 5.25
  • EBIDTA: $2.22 billion
  • Net Margins: 5.07%
  • Return on Equity: 23.45%
  • Return on Assets: 8.68%
  • Debt-to-Equity Ratio: 0.78%
  • Current Ratio: 0.87%
  • Quick Ratio: 0.59%
  • Average Volume: 6.39 million shs.
  • Beta: 1.1
  • Short Ratio: 1.48
Frequently Asked Questions for Boston Scientific Corporation (NYSE:BSX)

What is Boston Scientific Corporation's stock symbol?

Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific Corporation's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) posted its quarterly earnings data on Thursday, July, 27th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.27 EPS. View Boston Scientific Corporation's Earnings History.

When will Boston Scientific Corporation make its next earnings announcement?

Boston Scientific Corporation is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Boston Scientific Corporation.

What guidance has Boston Scientific Corporation issued on next quarter's earnings?

Boston Scientific Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $1.23-1.27 for the period, compared to the Thomson Reuters consensus estimate of $1.25. The company issued revenue guidance of $8.89-8.99 billion, compared to the consensus revenue estimate of $8.87 billion.Boston Scientific Corporation also updated its Q3 guidance to $0.29-0.31 EPS.

Where is Boston Scientific Corporation's stock going? Where will Boston Scientific Corporation's stock price be in 2017?

21 brokerages have issued twelve-month target prices for Boston Scientific Corporation's shares. Their forecasts range from $25.00 to $33.00. On average, they anticipate Boston Scientific Corporation's stock price to reach $29.91 in the next year. View Analyst Ratings for Boston Scientific Corporation.

What are analysts saying about Boston Scientific Corporation stock?

Here are some recent quotes from research analysts about Boston Scientific Corporation stock:

  • 1. According to Zacks Investment Research, "Over the past one month, Boston Scientific was trading below the Zacks categorized broader Medical Products industry. Adverse foreign exchange continues to pose challenges for Boston Scientific. We are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. The woes of challenging economy and competitive landscape continue to weigh the stock. However, on the positive side, the company is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets. The company recently received CE mark for its Vercise Gevia DBS System which is expected to boost its European business. The increased top line guidance for 2017 also buoys optimism." (7/11/2017)
  • 2. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
  • 3. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)

Who are some of Boston Scientific Corporation's key competitors?

Who are Boston Scientific Corporation's key executives?

Boston Scientific Corporation's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President
  • Timothy A. Pratt, Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management
  • Edward F. Mackey, Executive Vice President - Operations
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer
  • Michael P. Phalen, Executive Vice President; President - MedSurg
  • Wendy Carruthers, Senior Vice President - Human Resources

Who owns Boston Scientific Corporation stock?

Boston Scientific Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bollard Group LLC (2.46%), Diamond Hill Capital Management Inc. (0.22%), APG Asset Management N.V. (0.17%), Tavio Capital LLC (0.11%), Gateway Investment Advisers LLC (0.09%) and Atalanta Sosnoff Capital LLC (0.09%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt. View Institutional Ownership Trends for Boston Scientific Corporation.

Who sold Boston Scientific Corporation stock? Who is selling Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bollard Group LLC, APG Asset Management N.V., Diamond Hill Capital Management Inc., Great West Life Assurance Co. Can, PGGM Investments, Tributary Capital Management LLC, Atalanta Sosnoff Capital LLC and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Boston Scientific Corporation stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt. View Insider Buying and Selling for Boston Scientific Corporation.

Who bought Boston Scientific Corporation stock? Who is buying Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Vontobel Asset Management Inc., Barometer Capital Management Inc., Russell Investments Group Ltd., ING Groep NV, Mn Services Vermogensbeheer B.V., Lockheed Martin Investment Management Co., Moody Lynn & Lieberson LLC and Tavio Capital LLC. Company insiders that have bought Boston Scientific Corporation stock in the last two years include Charles J Dockendorff and John E Abele. View Insider Buying and Selling for Boston Scientific Corporation.

How do I buy Boston Scientific Corporation stock?

Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific Corporation's stock price today?

One share of Boston Scientific Corporation stock can currently be purchased for approximately $27.05.

MarketBeat Community Rating for Boston Scientific Corporation (NYSE BSX)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  501 (Vote Outperform)
Underperform Votes:  473 (Vote Underperform)
Total Votes:  974
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Boston Scientific Corporation (NYSE:BSX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $29.91 (10.56% upside)

Analysts' Ratings History for Boston Scientific Corporation (NYSE:BSX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Cowen and CompanyReiterated RatingOutperform$31.00LowView Rating Details
7/12/2017Royal Bank Of CanadaReiterated RatingBuy$31.00LowView Rating Details
6/28/2017J P Morgan Chase & CoReiterated RatingOverweight$27.00 -> $31.00LowView Rating Details
6/28/2017Stifel NicolausBoost Price TargetHold$30.00 -> $32.00LowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingHold$28.00LowView Rating Details
6/28/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
6/28/2017Barclays PLCBoost Price TargetOverweight -> Overweight$30.00 -> $31.00LowView Rating Details
6/22/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $32.00LowView Rating Details
6/21/2017BMO Capital MarketsReiterated RatingBuy$30.00LowView Rating Details
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 -> $28.50LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/6/2016Citigroup Inc.Boost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016Benchmark Co.Boost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of America CorporationReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche Bank AGReiterated RatingHoldN/AView Rating Details
2/25/2016SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Boston Scientific Corporation (NYSE:BSX)
Earnings by Quarter for Boston Scientific Corporation (NYSE:BSX)
Earnings History by Quarter for Boston Scientific Corporation (NYSE BSX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Boston Scientific Corporation (NYSE:BSX)
2017 EPS Consensus Estimate: $1.26
2018 EPS Consensus Estimate: $1.40
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.31$0.31
Q3 20176$0.30$0.32$0.31
Q4 20175$0.32$0.35$0.33
Q1 20182$0.29$0.30$0.30
Q2 20182$0.35$0.35$0.35
Q3 20183$0.34$0.37$0.36
Q4 20182$0.39$0.41$0.40
(Data provided by Zacks Investment Research)


Dividend History for Boston Scientific Corporation (NYSE:BSX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Boston Scientific Corporation (NYSE:BSX)
Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 92.11%
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.00View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.40View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.00View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.00View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.12View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.28View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Boston Scientific Corporation (NYSE:BSX)
Latest Headlines for Boston Scientific Corporation (NYSE:BSX)
DateHeadline logoBoston Scientific Corp Q2 Income Advances 19% - Nasdaq - July 27 at 5:19 PM logoEarnings Reaction History: Boston Scientific Corporation, 37.5 ... - Nasdaq - July 27 at 5:19 PM logoBoston Scientific tops Street 2Q forecasts - July 27 at 5:19 PM logoBoston Scientific Corporation (NYSE:BSX) Releases Earnings Results, Beats Expectations By $0.01 EPS - July 27 at 4:59 PM logo Analysts Expect Boston Scientific Corporation (NYSE:BSX) Will Post Quarterly Sales of $2.21 Billion - July 27 at 11:22 AM logoBoston Scientific Corporation (NYSE:BSX) Issues Q3 Earnings Guidance - July 27 at 11:13 AM logoBoston Scientific Corporation (BSX) Updates FY17 Earnings Guidance - July 27 at 11:12 AM logoBreakfast Technical Briefing on Medical Equipment Stocks -- Abbott ... - PR Newswire (press release) - July 26 at 5:22 PM logoZacks: Brokerages Anticipate Boston Scientific Corporation (NYSE:BSX) to Announce $0.31 EPS - July 26 at 12:28 AM logoBoston Scientific (BSX) Q2 Earnings: What Awaits the Stock? - Nasdaq - July 21 at 11:29 PM logoBoston Scientific joins in $36M round for Twin Cities med-tech startup - July 21 at 6:21 PM logoBoston Scientific (BSX) Q2 Earnings: What Awaits the Stock? - July 21 at 6:21 PM logoAbbott profit forecast gets a lift from St. Jude integration - Reuters - July 20 at 6:28 PM logoBoston Scientific Corporation (BSX) Set to Announce Earnings on Thursday - July 20 at 7:40 AM logoAxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer - July 17 at 7:31 AM logoFDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health - Benzinga - July 14 at 11:43 PM logoBoston Scientific Corporation (BSX) CFO Sells $2,532,501.84 in Stock - July 12 at 7:53 PM logo3 Red-Hot Medical Tech Stocks That Could Beat Earnings Estimates - 24/7 Wall St. - July 11 at 5:46 PM logoBoston Scientific Corporation (BSX) Downgraded to Buy at BidaskClub - July 8 at 1:02 PM logoClass Action Regarding Boston Scientific Transvaginal Mesh Devices Has Been Certified - July 8 at 9:28 AM logoBoston Scientific to Webcast Conference Call Discussing Second Quarter 2017 ... - July 6 at 6:00 PM logoTimothy A. Pratt Sells 10,000 Shares of Boston Scientific Corporation (NYSE:BSX) Stock - July 5 at 7:26 PM logoBoston Scientific to Webcast Conference Call Discussing Second Quarter 2017 Financial Results - July 5 at 5:32 PM logoEastman Chemical Achieves #89 Analyst Rank, Surpassing Boston Scientific - July 3 at 4:49 PM logoHow Has Boston Scientific Stock Performed Recently? - July 3 at 4:49 PM logoBoston Scientific Corporation (BSX) Given Consensus Rating of "Buy" by Analysts - July 3 at 12:56 PM logoBoston Scientific Corporation (BSX) PT Raised to $31.00 at Barclays PLC - July 2 at 12:38 PM logoBoston Scientific Corporation (NYSE:BSX) Stock Rating Upgraded by Zacks Investment Research - July 2 at 12:02 PM logoBoston Scientific Corporation (BSX) Expected to Announce Quarterly Sales of $2.21 Billion - July 1 at 8:16 AM logoWhat Analysts Recommend for Boston Scientific - June 30 at 4:51 PM logoHow Boston Scientific’s Alair System Performed in Trials - June 30 at 4:51 PM logoETFs with exposure to Boston Scientific Corp. : June 30, 2017 - June 30 at 4:50 PM logoBoston Scientific Corporation (BSX) to Post FY2019 Earnings of $1.51 Per Share, Jefferies Group Forecasts - June 30 at 12:25 PM logoEquities Analysts Issue Forecasts for Boston Scientific Corporation's Q3 2018 Earnings (BSX) - June 30 at 11:20 AM logo Brokerages Anticipate Boston Scientific Corporation (BSX) to Post $0.31 Earnings Per Share - June 29 at 8:32 PM logoBoston Scientific Corporation (BSX) EVP Sells $434,310.00 in Stock - June 29 at 7:49 PM logoFeatured Company News - Boston Scientific Outlined Sustained Growth Strategy; Set to Expand into New Markets and Product Portfolios - June 29 at 5:58 PM logoZacks Investment Research Lowers Boston Scientific Corporation (BSX) to Hold - June 29 at 11:54 AM logoQ1 2018 EPS Estimates for Boston Scientific Corporation (BSX) Lowered by Leerink Swann - June 29 at 10:32 AM logoBoston Scientific Corporation to Post Q4 2017 Earnings of $0.34 Per Share, Jefferies Group Forecasts (BSX) - June 29 at 10:08 AM logoSunTrust Banks Equities Analysts Increase Earnings Estimates for Boston Scientific Corporation (BSX) - June 29 at 8:16 AM logoBoston Scientific Corporation's (BSX) Hold Rating Reiterated at Oppenheimer Holdings Inc. - June 28 at 11:40 PM logoBoston Scientific Corporation's (BSX) "Overweight" Rating Reiterated at J P Morgan Chase & Co - June 28 at 9:52 PM logo5 Biggest Price Target Changes For Wednesday - Benzinga - June 28 at 9:49 PM logoBoston Scientific Corporation's (BSX) "Hold" Rating Reiterated at Stifel Nicolaus - June 28 at 2:32 PM logoJefferies Group LLC Reiterates "Hold" Rating for Boston Scientific Corporation (BSX) - June 28 at 2:32 PM logoSunTrust Banks Weighs in on Boston Scientific Corporation's FY2019 Earnings (BSX) - June 28 at 2:06 PM logoBoston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day - June 27 at 4:18 PM logoBoston Scientific Corporation's (BSX) "Neutral" Rating Reaffirmed at BTIG Research - June 27 at 11:34 AM logoBoston Scientific hosts Investor Day today; goal of 6-8% organic annual revenue growth and double-digit annual non-GAAP EPS growth next three years; shares up 1% - June 27 at 10:47 AM



Boston Scientific Corporation (BSX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff